BridgeBio Pharma Posts $1 Loss, Beats Q4 Revenue by 2.8%
BridgeBio Pharma posted an adjusted Q4 loss of $1.00 per share, missing estimates by 34% but improving from a $1.31 loss a year earlier. Revenue soared to $154.2 million, topping consensus by 2.8% and leaping from $5.9 million in Q4 2024.
1. Q4 Earnings Miss
BridgeBio Pharma reported an adjusted loss per share of $1.00 for the quarter ended December 2025, falling short of the expected $0.75 loss by 34% but narrowing from a $1.31 loss in the year-ago period. This marked the company’s second consecutive quarter of EPS underperformance versus consensus estimates.
2. Revenue Surge
Total Q4 revenue reached $154.18 million, exceeding the $150 million consensus by 2.8% and representing a dramatic increase from $5.88 million in Q4 2024. It was BridgeBio’s fourth straight quarter of revenue outperformance, driven by product launches and expanding rare disease pipeline contributions.
3. Outlook & Stock Performance
Analyst consensus for Q1 projects a $0.64 per share loss on $173.5 million in revenues, with full-year estimates at a $1.79 per share loss on $900.3 million. BridgeBio shares have declined 11.2% year-to-date, underperforming the roughly flat S&P 500 return.